Real-world study on HR+, HER2−, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns

by X. Pivot, F. Chartier, N. Chouaki, J. Brown, R. Williams, A. Rider
Published 2021-04-01

Breast cancer screening in France: results of the EDIFICE survey

by X Pivot, O Rixe, JF Morere, Y Coscas, L Cals, M Namer, D Serin, S Dolbeault, F Eisinger, C Roussel, JY Blay
Published 2008-01-01

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

by F. Bazan, E. Dobi, B. Royer, E. Curtit, L. Mansi, N. Menneveau, M. J. Paillard, G. Meynard, C. Villanueva, X. Pivot, L. Chaigneau
Published 2019-11-01

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phas...

by J. Gligorov, X. Pivot, B. Ataseven, M. De Laurentiis, A. Llombart, K.H. Jung, A. Manikhas, H.A. Azim, A. Alexandrou, K. Gupta, L. Herraez-Baranda, N. Tosti, E. Restuccia
Published 2021-04-01

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

by O. Adotevi, Y. Godet, J. Galaine, Z. Lakkis, I. Idirene, J. M. Certoux, M. Jary, R. Loyon, C. Laheurte, S. Kim, A. Dormoy, F. Pouthier, C. Barisien, F. Fein, P. Tiberghien, X. Pivot, S. Valmary-Degano, C. Ferrand, P. Morel, E. Delabrousse, C. Borg
Published 2018-05-01